In 2010, the authors of a double-blind, randomized, placebo-controlled trial of 60 children reported:
“The [BioGaia]-supplemented children had significantly lower pain intensity compared with the placebo controls . . . Supplementation with L. reuteri
[BioGaia] reduced perceived abdominal pain intensity, which may encourage clinicians to use this probiotic in children with FAP.”
BioGaia chewable tablets and drops bear Natural Product Numbers (NPNs)
80012472 and 80012473, respectively.